Your fact-checks will appear here
Monoclonal antibody
Dr. Sanjay Gupta is CNN’s chief medical correspondent, a practicing neurosurgeon and best‑selling author who has reported extensively on Alzheimer’s and brain health, including a 2023 book "Keep Sharp...
No reliable information about a therapy called "memo blast" is present in the supplied reporting, so its effects cannot be judged from these sources; the documents instead evaluate anti-amyloid monocl...
Neurocept has not received FDA approval for the treatment of cognitive decline or memory loss as of November 8, 2025; available materials consistently describe it as a dietary supplement or an investi...
Dr. Sanjay Gupta has publicly reported extensively on Alzheimer’s topics — including a CNN personal investigation, a CNN documentary “The Last Alzheimer’s Patient,” and commentary on treatments such a...
New disease‑modifying monoclonal antibodies for early Alzheimer’s—lecanemab (Leqembi) and donanemab (Kisunla)—are expensive at scale (Leqembi cited at $26,500/year; Kisunla initial pricing described a...
Dr. Sanjay Gupta has publicly presented a mix of cautious optimism about new drugs like Leqembi and a strong emphasis on lifestyle and “cognitive reserve” approaches to slow or reduce dementia risk. H...
APOE‑ε4 carrier status meaningfully raises the risk of amyloid‑related imaging abnormalities (ARIA) with both lecanemab and donanemab, and that elevated risk has been translated into mandatory APOE ge...
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
Two monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla)—offer modest slowing of early Alzheimer’s symptoms but carry specific, sometimes serious safety risks that require structured moni...
The documents provided show recent FDA approvals for anti-amyloid Alzheimer’s drugs — notably lecanemab (Leqembi) and donanemab (Kisunla/donanemab) — but contain no reporting that identifies or confir...
The core factual findings are simple: Leqembi (lecanemab) received and was , after a confirmatory trial demonstrated clinical benefit . Aduhelm (aducanumab) received , and public records in the datase...
As of 2025 the FDA’s approved arsenal for Alzheimer’s disease includes new anti-amyloid monoclonal antibodies for early-stage illness, longstanding symptom‑relief drugs, and a few recent approvals for...
Lecanemab and donanemab are monoclonal anti‑amyloid antibodies approved for early Alzheimer’s disease that produce modest slowing of decline but carry important and common safety risks—most notably am...
The randomized trials of lecanemab and donanemab showed statistically significant slowing of cognitive and functional decline over 18 months, but the absolute differences were small versus placebo and...
Dr. Sanjay Gupta’s recent reporting emphasizes lifestyle interventions and newer antibody drugs like Leqembi (lecanemab) as reasons for renewed hope, noting Leqembi clears amyloid plaques and slowed c...
Available sources do not report that a company or product named “Neurocept” ran clinical trials using amyloid PET, tau imaging, or CSF biomarkers as primary endpoints; the search returns consumer supp...
Neurocept’s primary endpoints are not mentioned in the supplied search results; available sources instead describe how aducanumab’s approval relied on a surrogate biomarker (amyloid reduction) while l...
Neurocept’s phase 3 data are not described in the provided sources; available material lists trial completion calendars and company financial reports but does not report Neurocept’s phase 3 primary en...
The claim that Neurocept has advanced to Phase 3 trials for Alzheimer’s is not supported by the available analyses: none of the inspected sources document a clear Phase 3 registration or readout for a...
Lecanemab, marketed as LEQEMBI or Leqembi, is a humanized IgG1 monoclonal antibody that targets aggregated amyloid‑beta protofibrils and plaques and is approved to treat (mild cognitive impairment or ...